Alterations of lung microbiota in patients with non-small cell lung cancer

Zeng, Wen; Zhao, Chengzhu; Yu, Mengge; Chen, Hailong; Pan, Yiyun; Wang, Yuhuan; Bao, Hejing; Ma, Hao; Ma, Shudong

doi:10.1080/21655979.2022.2045843

Cited by 19 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data in accordance with other studies revealed that in lung cancer patients, cumulative risk factors including chemotherapy and ICU admission correlated with severe outcomes in COVID-19 patients. 13 , 14 , 17 …”

Section: Discussionmentioning

confidence: 99%

“…Prevotella and Veillonella were most strongly associated with NSCLC, and Veillonella significantly intensified the progression of NSCLC in lung microbiota. 17 Persistence of Veillonella sp. and Prevotella spp.…”

Section: Discussionmentioning

confidence: 99%

“… 14 , 17 About 1.6 million lung cancer patients succumb each year to the disease, of which non-small cell lung cancer (NSCLC) is the prevalent type of lung cancer histology (induced by acquired environmental effects and host genetic factors). 17 Lung cancer describes a unique condition of cumulative risks for COVID-19 problems, such as advanced age, numerous comorbidities, prolonged smoking, lung tumors, and immunosuppressive treatment. 13 , 18 Subsequently, lung cancer patients may be more defenseless against viral infections with poor prognosis if COVID-19 is suspected.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gut-Lung Microbiota Characterization in Patients with Non-Small Cell Lung Carcinoma and COVID-19 Coinfection

Vakili,

Shoaei,

Shahzamani

et al. 2024

Arch Iran Med

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC) patients with COVID-19 have an excessive chance of morbidity and mortality. The fecal-nasopharyngeal microbiota compositions of NSCLC patients were assessed in this study. Methods: In total, 234 samples were collected from 17 NSCLC patients infected with COVID-19, 20 NSCLC patients without confirmed COVID-19, 40 non NSCLC patients with COVID-19, and 40 healthy individuals. Results: In lung microbiota, the abundance of Streptococcus spp. in NSCLC patients with confirmed COVID-19 was significantly higher than the two control groups. Pseudomonas aeruginosa and Staphylococcus aureus were listed as the most frequent pulmonary bacterial groups that colonized COVID-19 patients. In fecal specimens, the numbers of Bacteroidetes, Firmicutes, and Actinobacteria phyla were significantly higher amongst NSCLC patients with COVID-19. NSCLC patients infected with COVID-19 showed lower levels of Lactobacillus spp., Akkermansia muciniphila, and Bifidobacterium spp. The counts of Streptococcus spp., in NSCLC patients with COVID-19 were significantly higher than those of healthy individuals (8.49±0.70 log CFU/g wet feces vs 8.49±0.70 log CFU/g wet feces). Prevotella spp. were enriched in the gut and respiratory tracts of COVID-19 patient groups. The unbiased analysis showed an increment in Enterococcus spp., Streptococcus spp., and Prevotella spp. Conclusion: Eventually, it was found that compared to control groups, COVID-19 patients with NSCLC showed diminished gut bacteria diversity and increase in Lactobacillus spp., A. muciniphila, and Bifidobacterium spp. The overgrowth of Enterococcus spp., Streptococcus spp., and Prevotella spp. could be potential predictive biomarkers in the gut-lung axis of NSCLC patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gut-Lung Microbiota Characterization in Patients with Non-Small Cell Lung Carcinoma and COVID-19 Coinfection

Vakili,

Shoaei,

Shahzamani

et al. 2024

Arch Iran Med

View full text Add to dashboard Cite

show abstract

“…Further, we found nine genera including seven Firmicutes genera ( Staphylococcus , Streptococcus , Lactobacillus , Bacillus , Turicibacter , Clostridium_sensu_stricto_1 , Pediococcus ) were significantly enriched in MPE individuals. Lung and gut Firmicutes have been found to be a useful microbial signature lung cancer in several studies 41–43 . Several Firmicutes members including genus Streptococcus , 44–46 Staphylococcus , 44 Lactobacillus , 47,48 and Pediococcus 48 have recently been implicated in lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma

Huang

Zhuo

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

Background Lung cancer is the most common cancer‐related death worldwide. In 2022, the number of daily deaths of lung cancer was estimated to reach around 350 in the United States. Lung adenocarcinoma is the main subtype of lung cancer and patients with malignant pleural effusion (MPE) suffer from poor prognosis. Microbiota and its metabolites are associated with cancer progression. However, the effect of pleural microbiota on pleural metabolic profile of MPE in lung adenocarcinoma patients remains largely unknown. Methods Pleural effusion samples collected from lung adenocarcinoma patients with MPE (n = 14) and tuberculosis pleurisy patients with benign pleural effusion (BPE group, n = 10) were subjected to microbiome (16S rRNA gene sequencing) and metabolome (liquid chromatography tandem mass spectrometry [LC‐MS/MS]) analyses. The datasets were analyzed individually and integrated for combined analysis using various bioinformatic approaches. Results The metabolic profile of MPE in lung adenocarcinoma patients were clearly distinguished from BPE with 121 differential metabolites across six significantly enriched pathways identified. Glycerophospholipids, fatty and carboxylic acids, and derivatives were the most common differential metabolites. Sequencing of microbial data revealed nine significantly enriched genera (i.e., Staphylococcus, Streptococcus, Lactobacillus) and 26 enriched ASVs (i.e., species Lactobacillus_delbrueckii) in MPE. Integrated analysis correlated MPE‐associated microbes with metabolites, such as phosphatidylcholine and metabolites involved in the citrate cycle pathway. Conclusion Our results provide substantial evidence of a novel interplay between the pleural microbiota and metabolome, which was drastically perturbed in MPE in lung adenocarcinoma patients. Microbe‐associated metabolites can be used for further therapeutic explorations.

show abstract

“…Increasing studies suggest that smoking, chronic airway inflammation, and pulmonary fibrosis are major drivers of lung cancer and are recognized to alter the microbiota and lung cancer progression [68]. Although decades of research have demonstrated a certain link between the microbiome and cancer, the specific mechanism of how the microbiome leads to lung cancer is still poorly understood.…”

Section: Microbiome‐driven Mechanisms Of Lung Cancermentioning

confidence: 99%

The microbiome in the pathogenesis of lung cancer

Miao,

Qiu

2023

APMIS

View full text Add to dashboard Cite

As one of the malignant tumors with high incidence rate and high mortality, lung cancer seriously threatens the life safety of patients. Research shows that microorganisms are closely related to lung cancer. The microbiome is symbiotic with the host and plays a vital role in the functions of the human body. Microbiota dysbiosis is correlated with development of lung cancer. However, the underlying mechanisms are poorly understood. This paper summarizes the composition characteristics of the gut–lung axis microbiome and intratumoral microbiome in patients with lung cancer. We then expound five potential carcinogenic mechanisms based on microorganisms, such as genotoxicity, metabolism, inflammation, immune response, and angiogenesis. Next, we list three high‐throughput sequencing methods, and finally looks forward to the prospect of microorganisms as novel targets for early diagnosis and treatment of lung cancer.

show abstract

Alterations of lung microbiota in patients with non-small cell lung cancer

Cited by 19 publications

References 38 publications

Gut-Lung Microbiota Characterization in Patients with Non-Small Cell Lung Carcinoma and COVID-19 Coinfection

Gut-Lung Microbiota Characterization in Patients with Non-Small Cell Lung Carcinoma and COVID-19 Coinfection

Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma

The microbiome in the pathogenesis of lung cancer

Contact Info

Product

Resources

About